ROC curve analysis enabled us to identify that baseline IGFBP-2 of 105 ng/ml discriminate the two subgroup of SSc patients (AUC = 0.75 at 80% sensibility and 75% specificity, p = 0.028) (Fig. 4e). This evidence concerns the gene IGFBP2 and systemic sclerosis.